不同浓度阿托品滴眼液控制儿童青少年近视进展的Meta分析

目的:评估已发表的关于不同浓度的阿托品滴眼液延缓儿童青少年近视进展的有效性。方法:搜集PubMed、the Cochrane Library、Embase、中国知网、维普和万方数据库内建库至2022-05阿托品滴眼液治疗儿童青少年近视的随机对照试验(RCT)。对纳入文献采用《Cochrane干预措施系统评价手册》中偏倚风险评价工具进行质量评价;采用Review Manager 5.4软件进行Meta分析。结果:共纳入14项RCT研究,包含3 946例儿童青少年受试者。Meta分析结果显示：与对照组相比,不同浓度阿托品滴眼液均可延缓儿童青少年近视进展。1%、0.5%、0.05%、0.02%、0.01%阿托品滴眼液组的眼轴增长量均低于对照组,差异均有统计学意义(MD=-0.34,95%CI:-0.39～-0.29,P<0.00001;MD=-0.51,95%CI:-0.79～-0.24,P=0.0003;MD=-0.17,95%CI:-0.30～-0.04,P=0.01;MD=-0.21,95%CI:-0.30～-0.11,P<0.0001;MD=-0.09,95%CI:-0....     

环喷托酯和阿托品对近视儿童睫状肌麻痹效应的Meta分析

目的:系统评价环喷托酯和阿托品应用于近视儿童验光前的睫状肌麻痹效应和安全性。方法:在PubMed、EMBASE、Web of Science、The Cochrane Library、中国知网(CNKI)、万方数据库中检索自建库至2020-04发表的关于比较环喷托酯与阿托品用于近视儿童睫状肌麻痹效果的相关文献。对于筛选出来的文献,经资料提取和质量评价后,采用RevMan5.3软件进行Meta分析。结果:本研究最终纳入9篇文献,其中使用阿托品者588眼,使用环喷托酯者592眼。Meta分析结果显示,近视儿童验光前使用环喷托酯和阿托品进行睫状肌麻痹后屈光度[WMD=-0.01,95%CI(-0.30,0.27),P=0.93]和残余调节力[WMD=0.22,95%CI(-0.13,0.58),P=0.22]均无差异,但环喷托酯不良反应发生率较低,更安全。结论:环喷托酯与阿托品对近视儿童的睫状肌麻痹作用相当,且安全性较高,可以替代阿托品对近视儿童在验光前使用。     

低能量红光对近视儿童脉络膜厚度和等效球镜度及眼轴长度的影响

目的:系统评价低能量红光对于近视儿童脉络膜厚度(ChT)和等效球镜度(SE)及眼轴长度(AL)的影响。方法:通过检索Pubmed、Embase、Cochrane Library、Web of Science、中国知网、万方、维普网及中国生物医学文献数据库共8个数据库,从建库至2023-01期间所有关于低能量红光干预近视发展的随机对照试验,红光干预作为试验组,仅配戴单焦眼镜作为对照组。按照Cochrane手册要求进行文献质量及偏倚风险评价。Meta分析由Revman5.4软件完成。结果:共计纳入8篇有关低能量红光干预近视发展的随机对照试验研究。用于分析ChT变化的样本量为红光组407眼,对照组425眼;用于分析SE变化差值的样本量为红光组490眼,对照组518眼;纳入AL分析的样本量为红光组518眼,对照组539眼。红光组与对照组ChT、SE、AL比较均有差异(ChT:WMD=37.81,95%CI:21.55～54.07,P<0.001;SE:WMD=0.58,95%CI:0.46～0.71,P<0.001;AL:WMD=-0.31,95%CI:-0.39～-0.24,P&...     

不同浓度阿托品对中国儿童近视控制效果的Meta分析

目的 系统评价不同浓度阿托品对中国儿童近视的控制效果。方法 计算机检索PubMed、Embase、The Cochrane Library、Web of Science、CBM、WanFang Data、VIP和CNKI数据库,搜集关于阿托品控制儿童近视的研究,检索时限均从建库至2023年4月。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.4软件进行Meta分析。结果 共纳入32项研究,包括7种不同浓度阿托品对比安慰剂的结果。Meta分析结果显示,与安慰剂相比,0.1 g·L^-1阿托品对等效球镜度变化有显著的影响[MD=0.39,95%CI(0.26,0.52),P<0.05],能够显著抑制眼轴长度的增加[MD=-0.18,95%CI(-0.24,-0.12),P<0.05]。其他浓度中,0.2 g·L^-1、0.5 g·L^-1及10 g·L^-1阿托品均对近视的控制均有较好的效果。结论 现有证据显示,与安慰剂相比,0.1 g·L^-1     

角膜塑形镜控制青少年近视有效性及安全性的Meta分析

目的 就角膜塑形镜对青少年近视患者的有效性及安全性进行Meta分析。方法 循证医学研究。以2017年1月前发表的角膜塑形镜控制儿童近视进展有效性和安全性的临床资料为目标,检索Medline及中国知网、万方数据库。通过Stata 11.0对文献进行Meta分析。计算1年和2年时间的眼轴长度改变的加权均数差（WMD）和不良反应发生率的比值比（OR及95%CI）,并按研究类型、种族、测量仪器等因素进行亚组分析。结果 共纳入14项研究,病例共2 563例,其中塑形镜组1 339例,框架镜组1 224例。Meta分析结果显示：2年观察中,塑形镜组和框架镜组眼轴的变化量有显著差异,WMD=-0.361,95%CI：-0.604~0.118,1年观察中,塑形镜组和框架镜组眼轴的变化量有显著差异,WMD=-0.356,95%CI：-0.610~-0.102。随访1年后塑形镜组近视控制率为66.6%,随访2年后为51.3%[近视控制率=（塑形镜组眼轴变化量-框架镜组眼轴变化量）/框架镜组眼轴变化量]。2年随访时间内,塑形镜组和框架镜组不良反应发生率的OR=6.408,95%CI：2.460~16.688。结论 角膜塑形镜是一个有效且相对安全的控制儿童近视进展的方法。     

角膜塑形镜治疗亚洲儿童近视有效性和安全性的Meta分析

目的：系统评价角膜塑形镜治疗亚洲儿童近视的有效性和安全性。

方法：检索The Cochrane Library、Medline、EMbase、CBM、CNKI、VIP和WanFang数据库,语种限定为中英文。采用Cochrane手册提供的偏倚风险评价工具和MINORS(methodological index for non-randomized studies)量表分别评价纳入文献(随机对照试验和对照试验)的质量; 采用漏斗图检测纳入文献的发表偏倚; 采用RevMan 5.3软件进行Meta分析。

结果：共有7篇文献符合纳入排除标准,包含478例研究对象(角膜塑形镜组250例,对照组228例)。Meta分析结果显示：角膜塑形镜对控制眼轴长度增加方面优于单光镜,两组之间的差异具有统计学意义\〖WMD=-0.31,95%CI(-0.35,-0.26),P<0.001\〗。5篇文献观察了不良反应,均报道有中等程度角膜荧光素染色阳性的不良反应,一篇报道有1例患儿出现睑板腺囊肿,未见严重不良反应报道。

结论：角膜塑形镜可有效控制亚洲儿童近视的发展,且较为安全。     

0.01%阿托品联合角膜塑形镜对于延缓青少年近视进展的Meta分析

目的：评估0.01%阿托品联合角膜塑形镜对于延缓青少年近视进展的疗效。方法：循证医学研究。 检索2016年2月至2021年2月在中国期刊全文数据库、中国维普全文数据库、中国生物医学文献服 务系统、万方数据库、PubMed、The Cochrane Library和EMbase等各大数据库中的相关文献。经过 筛选、统计数据后,将数据导入RevMan 5.4数据库进行统计学分析,应用均值、标准差,计算各个 研究数据的均值差和95%置信区间（95%CI）,评估比较0.01%阿托品联合配戴角膜塑形镜和仅配戴 角膜塑形镜干预前后眼轴长度、等效球镜度（SE）、瞳孔直径的变化。结果：检索得到144篇文献, 经过筛选后纳入9篇随机对照文献,共858例,9篇文献均分为试验组和对照组,试验组为0.01%阿 托品联合配戴角膜塑形镜,对照组为单独配戴角膜塑形镜。Meta分析结果显示,6篇文献记录干预 1年后眼轴长度的变化,经敏感性分析后剔除1篇文献,重新分析发现试验组干预前后眼轴长度变化 量小于对照组,差异有统计学意义[均值差（MD）=-0.17,95%CI（-0.22,-0.17）,P<0.001];4篇文 献记录了干预前后SE的变化,试验组SE变化量小于对照组,差异有统计学意义[MD=-0.16,95%CI （0.09,0.22）,P<0.001];3篇文献记录了瞳孔直径的变化,试验组瞳孔直径变化大于对照组,差异有 统计学意义[MD=0.70,95%CI（0.41,0.98）,P<0.001]。结论：相较于单独配戴角膜塑形镜,采用0.01% 阿托品联合角膜塑形镜的方法在控制青少年近视进展方面效果更佳。     

不同浓度阿托品延缓近视儿童等效球镜度及眼轴长度效果的Meta分析

目的：系统评价眼用0.01%、0.025%和0.05%阿托品对于近视儿童等效球镜度及眼轴长度的影响。

方法：检索PubMed、Embase、Cochrane Library、Web of Science、中国知网、万方数据库、维普网、中国生物医学文献数据库中从建库至2022-05期间发表的关于0.01%、0.025%和0.05%阿托品进行近视控制的研究。使用Cochrane手册对纳入文献进行偏倚风险评价及质量评价,并使用Revman 5.4软件进行Meta分析,利用STATA12.0软件检测发表偏倚。

结果：共计纳入6篇文献1 239眼,其中5项为随机对照试验,1项为病例对照研究。Meta分析显示,0.025%阿托品对SE及AL的抑制效果好于0.01%阿托品(SE：WMD=-0.15,95%CI：-0.23～-0.06,P<0.001; AL：WMD=0.07,95%CI：0.03～0.10,P<0.001)。0.05%阿托品对SE及AL抑制效果好于0.01%阿托品(SE：WMD=-0.35,95%CI：-0.44～-0.26,P<0.001; AL：WMD=0.16,95%CI：0.12～0.20,P<0.001)。0.05%阿托品对SE及AL增加的抑制效果好于0.025%阿托品(SE：WMD=-0.20,95%CI：-0.28～-0.11,P<0.001; AL：WMD=0.09,95%CI：0.06～0.12,P<0.001)。

结论：0.05%阿托品对SE及AL的控制效果优于0.025%及0.01%阿托品,但长期使用的副作用仍有待进一步观察。     

不同年龄近视儿童使用0.01%阿托品滴眼液的有效性观察

目的:评价0.01%阿托品滴眼液控制不同年龄儿童近视进展的有效性。方法:随机、双盲、安慰剂平行对照、单中心临床研究。纳入2019-05/2020-05就诊于本院的年龄6～13周岁,近视球镜度数-0.5～-6.00D,散光度数≤2.0D的近视儿童295例,以2∶1的比例随机分配到试验组(197例)和对照组(98例),试验组和对照组按年龄又分为6～8岁(40例/26例)、9～10岁(84例/34例)及11～13岁(73例/38例)三个亚组,试验组每晚睡前点0.01%阿托品滴眼液,对照组每晚睡前点安慰剂。比较两组患者治疗前、治疗2wk, 3、6、9及12mo各指标变化情况。治疗2wk仅行眼压、调节幅度、最佳矫正远/近视力、瞳孔直径及泪膜检查;治疗前,治疗6及12mo行睫状肌麻痹验光。结果:治疗12mo后,试验组等效屈光度及眼轴变化分别为-0.37±0.69D及0.29±0.24mm,对照组为-0.59±0.65D及0.37±0.23mm(P=0.008、0.006)。两组间等效屈光度和眼轴变化比较6～8岁无差异(t=0.054,P=0.957;t=-0.623,P=0.536);9～10岁有...     

玻璃体切除术前注射抗VEGF类药物治疗PDF的疗效及安全性的Meta分析

目的:探究增殖性糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)患者行玻璃体切除术治疗前玻璃体腔内注射抗VEGF类药物的有效性与安全性.方法:全面检索EMbase、The Cochrane Library、Pubmed、中国生物医学文摘数据库(CBM)、万方数据库(WanFang Database)、中国期刊全文数据库(CNKI)等数据库,检索时限均从建库至2017-01,语种不限,检索文献类型为随机对照试验;采用Jadad量表及Cochrane协作网提供的风险偏倚评估工具评价所纳入研究的质量,采用GRADEpro软件对各评价指标的参数进行循证医学质量评价;采用漏斗图检测所纳入文献的发表偏倚;最后采用Review Manager 5.3软件行Meta分析.结果:最终纳入发表时间介于2008/2016的16篇随机对照试验文献.共包含923例患眼,其中493例患眼进入PPV联合术前玻璃体腔内注射anti-VEGF组(试验组),430例患眼进入单纯行PPV组(对照组).Meta分析结果显示:(1)试验组术中出血的发生概率明显低于对照组[OR=0.06,95%CI(0.02~0.15),P<0.01],两组之间的差异具有统计学意义.(2)试验组手术持续时间明显短于对照组[WMD=-29.13,95%CI(-36.95~-21.30),P<0.01],两组之间的差异具有统计学意义.(3)试验组术后早期[OR=0.29,95%CI(0.19~0.44),P<0.01]及晚期[OR=0.34,95%CI(0.20~0.58),P<0.01]玻璃体出血的概率均低于对照组,两组之间的差异均具有统计学意义.(4)试验组术后最佳矫正视力水平不优于对照组[WMD=-0.51(LogMAR),95%CI(-1.10~0.08),P=0.09],两组之间的差异无统计学意义.(5)试验组术中医源性视网膜破裂发生概率低于对照组[OR=0.24,95%CI(0.14,0.40),P<0.01],两组之间的差异具有统计学意义.(6)在纳入的16篇文献共493例试验组患眼中,无1例报道出现与注射anti-VEGF类药物相关的明显眼内及全身不良反应.结论:PDR患者行玻璃体切除术治疗前玻璃体腔内注射抗VEGF类药物是安全、有效的治疗措施,能够显著减少术中及术后并发症的发生概率,改善患者的整体治疗效果.其具体的实施方案,如注射药物的剂量、玻璃体腔内注射与手术的间隔时间等,还有待进一步的探索与完善.     

Atropine 0.01% eye drops slow myopia progression: a systematic review and Meta-analysis

AIM: To evaluate the effects of atropine 0.01% on slowing myopia progression. METHODS: We searched for relevant studies in the Cochrane Library, PubMed, Embase, Ovid, CBM, CNKI, VIP and Wan Fang Data in Chinese. A supplementary search was conducted in OpenGrey (System for Information on Grey Literature in Europe), the ISRCTN registry, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP) from the dates of inception to June 30, 2018. RESULTS: Seven randomized controlled trials (RCTs) with a total of 1079 subjects were included (505 in the atropine 0.01% group and 574 in the control group). The results showed that the atropine 0.01% group exhibited significantly greater control of axial growth than the control group [MD=-0.12, 95%CI (-0.19, -0.06)]. There was also a statistically significant difference between the atropine 0.01% and control groups in the changes in axial length [MD=-0.14, 95%CI (-0.25, -0.03)], but the quality of evidence was low. There were no significant differences between the atropine 0.01% and control groups in the overall effect with respect to diopter value, change in diopter, distance vision and intraocular pressure [MD=0.08, 95%CI (-0.27, 0.42); MD=0.09, 95%CI (-0.17, 0.36); MD= -0.01, 95%CI (-0.02, 0.00); MD=0.08, 95%CI (-0.56,0.40)]. The sensitivity analysis showed that the conclusion of the Meta-analysis is relatively stable. With respect to adverse events, there were significant differences between the atropine 0.01% and control groups [OR=0.26, 95%CI (0.11, 0.61)]. CONCLUSION: Based on the available evidence, atropine 0.01% eye drops offer benefits in controlling axial growth and safety without causing significant differences in diopter values, distance vision and intraocular pressure.     

Effectiveness of peripheral defocus spectacle lenses in myopia control: a Meta-analysis and systematic review

AIM: To evaluate the effectiveness of peripheral defocus spectacle lenses (PDLs) in myopia control. METHODS: Literature retrieval on PubMed, Cochrane Library, Embase, and Web of Science databases, and the search time limit was from the establishment of each database to December 29, 2021 were conducted. Change of spherical equivalent refraction (SER) and axial change (AL) were extracted from the literatures that met the inclusion criteria, and RevMan5.3 software was used for Meta-analysis. RESULTS: A total of 4 randomized controlled trials (RCTs) were included in this Meta-analysis, involving 770 myopic children. The results showed that PDLs could delay the progression of myopia in children with myopia compared with single vision spectacle lenses (SVLs; WMD=0.21 D, 95%CI: 0.01, 0.41, P=0.04). However, there was no significant difference in controlling the growth of axial length (AL) in myopic children (WMD=-0.10 mm, 95%CI: -0.21, 0.01, P=0.07). The results of the effectiveness of myopia control between the two spectacle lenses showed that PDLs were more effective in controlling the progression of myopia (OR=5.73, 95%CI: 2.58, 12.70, P<0.001) and delaying the growth of AL (OR=44.25, 95%CI: 8.84, 221.58, P<0.001) than SVLs, and the differences were statistically significant. CONCLUSION: PDLs can control the progression of myopia compared with SVLs, but cannot delay the growth of AL, and the effectiveness of PDLs in myopia control better than SVLs.     

Choroidal thickness, myopia, and myopia control interventions in children: a Meta-analysis and systemic review

AIM: To investigate changes of choroidal thickness (ChT) in children with myopia and the effect of current myopia control interventions on ChT. METHODS: Major literature databases were searched for studies relevant to myopia in children. All studies used swept-source optical coherence tomography (SS-OCT) or enhanced depth imaging optical coherence tomography (EDI-OCT) to measure the ChT value. The weighted mean difference (WMD) and 95% confidence interval (CI) were pooled to evaluate ChT in myopia children. RESULTS: A total of 11 eligible articles, including 1693 myopic and 1132 non-myopic eyes, were included in the first Meta-analysis. The sub-foveal choroidal thickness (SFCT; WMD=-40.06, 95%CI, -59.36 to -20.75, P<0.001) and ChT at other sectors were significantly thinner in myopic eyes compared with the non-myopic eyes. The Meta-analysis revealed that the ChT decreased horizontally from the temporal sector toward the nasal sector in the pediatric myopia population. Another 11 studies reporting the effect of myopia control interventions were included in the second Meta-analysis for the relationship between myopia control treatments and ChT. SFCT significantly increased after orthokeratology (OK) treatment and OK combined with 0.01% atropine (OKA) treatment (WMD=19.47, 95%CI, 15.96 to 22.98, P<0.001; WMD=21.81, 95%CI, 12.92 to 29.70, P<0.001, respectively). The forest plots showed that SFCT changed little in myopic children receiving 0.01% atropine (P=0.30). Furthermore, the Meta-analysis showed that OK treatment had a stronger effect on the value of SFCT in myopic children as compared with 0.01% atropine (WMD=9.86; 95%CI, -0.21 to 19.93, P=0.05). There is no difference between the treatment with OK and OKA treatment in ChT in myopic children (P=0.37). CONCLUSION: The ChT in myopic eyes is thinner than that in non-myopic eyes in pediatric population. Myopia control interventions including OK and OKA lead to ChT thickening, but other treatments such as 0.01% atropine did not show an increase in ChT.     

The optimal atropine concentration for myopia control in Chinese children: a systematic review and network Meta-analysis

AIM: To figure out whether various atropine dosages may slow the progression of myopia in Chinese kids and teenagers and to determine the optimal atropine concentration for effectively slowing the progression of myopia. METHODS: A systematic search was conducted across the Cochrane Library, PubMed, Web of Science, EMBASE, CNKI, CBM, VIP, and Wanfang database, encompassing literature on slowing progression of myopia with varying atropine concentrations from database inception to January 17, 2024. Data extraction and quality assessment were performed, and a network Meta-analysis was executed using Stata version 14.0 Software. Results were visually represented through graphs. RESULTS: Fourteen papers comprising 2475 cases were included; five different concentrations of atropine solution were used. The network Meta-analysis, along with the surface under the cumulative ranking curve (SUCRA), showed that 1% atropine (100%)>0.05% atropine (74.9%) >0.025% atropine (51.6%)>0.02% atropine (47.9%)>0.01% atropine (25.6%)>control in refraction change and 1% atropine (98.7%)>0.05% atropine (70.4%)>0.02% atropine (61.4%)>0.025% atropine (42%)>0.01% atropine (27.4%)>control in axial length (AL) change. CONCLUSION: In Chinese children and teenagers, the five various concentrations of atropine can reduce the progression of myopia. Although the network Meta-analysis showed that 1% atropine is the best one for controlling refraction and AL change, there is a high incidence of adverse effects with the use of 1% atropine. Therefore, we suggest that 0.05% atropine is optimal for Chinese children to slow myopia progression.     

1%阿托品不同用药方式对控制青少年低度近视进展的远期效果

 目的 探讨1%阿托品凝胶的不同用药方式对控制青少年低度近视发展的影响。设计 前瞻性比较性病例系列。研究对象 2011年1-4月就诊的9~12岁之间,屈光度数在-0.50~-1.50 DS之间的青少年150例（300眼）。方法 根据随机数字表法将患者随机分为3组,每组50例。A组为对照组：每晚使用1次1%阿托品凝胶。B组：每周使用2次。C组：每周使用1次。观察2年,每3个月复查。主要指标 视力、屈光度、眼压、眼轴长度。结果 133例完成了2年的观察。其中A组38例,B组47例,C组48例。失访率11.3%。3组经治疗后近视屈光度进展分别为（-0.33±0.11）D、（-0.36±0.13）D和（-0.62±0.30）D;眼轴增长分别为（0.32±0.08）mm、（0.33±0.10）mm和（0.48±0.17）mm。A组与B组球镜屈光度、眼轴长度变化较少,差异均无统计学意义（P均>0.05）。C组患者视力下降,屈光度增加,眼轴变长,与A、B组比较差异均有统计学意义（P 均<0.05）。结论 1%阿托品凝胶长期滴眼能有效控制青少年低度数近视进展,每天用药与每周2次用药效果无显著性差异。每周2次用药患者耐受程度高,是比较适宜的给药方式。（眼科, 2014, 23： 111-114）     

Short-term effect of 0.01% atropine sulphate eye gel on myopia progression in children

AIM: To investigate the effect of 0.01% atropine sulphate eye gel on myopia progression and axial elongation in a 6-month treatment in children. METHODS: Totally 185 children aged 6-12y with binocular myopia of 3.0 D or less in both eyes were enrolled in this prospective cohort study. The atropine group (n=125) received one drop of 0.01% atropine sulphate eye gel in each eye before bedtime daily. The control group included 60 matched children without drug intervention during the same period. The spherical equivalent and axial length was recorded at baseline and the sixth month of treatment. The efficacy was evaluated by the change of the spherical equivalent and axial length. Adverse events were also recorded. RESULTS: The average spherical equivalent and axial length at baseline were not statistically significant between the atropine group (-1.64±0.80 D, 24.13±0.76 mm) and the control group (-1.59±0.94 D, 24.06±0.77 mm, P>0.05). After 6mo, there was significantly difference in the spherical equivalent progression between the atropine and the control group (-0.27±0.33 vs -0.60±0.35 D, P<0.001), with a relative reduction of 55.0% in myopia progression. The increase in axial elongation in the atropine group was significantly less than control group (0.19±0.14 vs 0.26±0.14 mm, P<0.001), with a relative reduction of 26.9% in axial length. The 84.4% and 38.4% of the eyes progressed by less than 0.50 D and remained stable in the atropine group, compared with 51.7% and 4.2% in the control group. No adverse events were observed. CONCLUSION: Atropine sulphate eye gel 0.01% can slow down myopia progression and axial elongation in children with a 6-month treatment.     

角膜塑形镜、低浓度阿托品与框架眼镜控制青少年近视的疗效比较

目的：对比观察角膜塑形镜、低浓度阿托品与框架眼镜控制青少年近视发展的疗效。

方法：选取2016-1/2016-07我科收治的青少年近视患者120例240眼,采取自愿原则分为3组：角膜塑形镜组40例80眼、低浓度阿托品组40例80眼、框架眼镜组40例80眼。随访18mo,对比分析三组患者的屈光度及眼轴变化情况。

结果：治疗18mo后,角膜塑形镜组、低浓度阿托品组的屈光度均低于框架眼镜组(P<0.05); 角膜塑形镜组、低浓度阿托品组治疗前后屈光度差值均低于框架眼镜组(P<0.05),但角膜塑形镜组与低浓度阿托品组比较,差异无统计学意义(P>0.05)。治疗18mo后,角膜塑形镜组、低浓度阿托品组眼轴均低于框架眼镜组(P<0.05); 角膜塑形镜组、低浓度阿托品组治疗前后眼轴差值均低于框架眼镜组(P<0.05),但角膜塑形镜组与低浓度阿托品组比较,差异无统计学意义(P>0.05)。

结论：角膜塑形镜与低浓度阿托品均可有效控制青少年近视患者屈光度和眼轴长度进展,其疗效均优于框架眼镜,但角膜塑形镜与低浓度阿托品控制近视的疗效无明显差异。